author-photo

Nils Homann

University of Lübeck

105

Papers

1424

Citations

Citation Trend

Filter By

Papers (105) Sort By

JournalConferenceOthers

1430P Frequency of PD-L1 positivity and microsatellite instability (MSI) in the DANTE trial: Perioperative atezolizumab with FLOT versus FLOT alone in patients with resectable esophagogastric adenocarcinoma. A randomized, open-label phase IIb trial of the German gastric group at the AIO and SAKK

2021 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
1429P Pathological regression in patients with microsatellite instability (MSI) receiving perioperative atezolizumab in combination with FLOT vs. FLOT alone for resectable esophagogastric adenocarcinoma: Results from the DANTE trial of the German Gastric Group at the AIO and SAKK

2021 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Trastuzumab in combination with 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) as perioperative treatment for patients with HER2-positive locally advanced esophagogastric adenocarcinoma: A phase II trial of the AIO Gastric Cancer Study Group.

2021 International Journal of Cancer
Show All
- Source
- Cite
- Save
Citations (3)
Pazopanib with 5-FU and oxaliplatin as first line therapy in advanced gastric cancer: A randomized phase-II study-The PaFLO trial. A study of the Arbeitsgemeinschaft Internistische Onkologie AIO-STO-0510.

2021 International Journal of Cancer
Show All
- Source
- Cite
- Save
Citations (0)
Perioperative ramucirumab in combination with FLOT versus FLOT alone for resectable esophagogastric adenocarcinoma (RAMSES/FLOT7): Results of the phase II-portion—A multicenter, randomized phase II/III trial of the German AIO and Italian GOIM.

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (8)
Safety of perioperative atezolizumab in combination with FLOT versus FLOT alone in patients with resectable esophagogastric adenocarcinoma: An interim safety analysis of the DANTE, a randomized, open-label phase II trial of the German Gastric Group at the AIO and the SAKK.

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (3)
Real-life results from the prospective QoliXane trial of the platform for outcome, quality of life, and translational research on pancreatic cancer (PARAGON) registry.

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1)
Interim safety analysis of the DANTE trial: Perioperative atezolizumab in combination with FLOT versus FLOT alone in patients with resectable esophagogastric adenocarcinoma—A randomized, open-label phase II trial of the German Gastric Group at the AIO and SAKK.

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (4)
Radiochemotherapy with or without cetuximab for unresectable esophageal cancer: final results of a randomized phase 2 trial (LEOPARD-2).

2020 Strahlentherapie Und Onkologie
Show All
- Source
- Cite
- Save
Citations (3)
Quality of Life and outcome of patients with metastatic pancreatic cancer receiving first-line chemotherapy with nab-paclitaxel and gemcitabine: Real life results from the prospective QOLIXANE trial of the Platform for Outcome, Quality of Life, and Translational Research on Pancreatic Cancer (PARAGON) registry.

2020 International Journal of Cancer
Show All
- Source
- Cite
- Save
Citations (2)

© Copyright 2015-2020 Acemap, Inc. Shanghai Jiao Tong University.

沪ICP备18028330号